Key points – Rituximab exposure decreased as metabolic tumor volume increased, and correlated with metabolic response and survival. Rituximab dose could be individualized according to metabolic tumor volume to achieve optimal exposure and therefore optimal response.
Home / Resource Library / Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients